Skip to main content

Table 4 Safety profile of DAAs regimens

From: Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders

 Patients (N = 144)Group A (N = 101)Group B (N = 43)p-value
At least 1 adverse event,n(%)60 (41,6%)49 (48.5%)11 (25.6%)0.015
> 2 adverse events,n(%)7 (4.8%)6 (5.9%)1 (2.3%)0.674
Severe adverse events,n(%)10 (6.9%)8 (7.9%)2 (4.6%)0.723
Adverse events leading to discontinuation,n(%)3 (2.1%)2 (1.9%)1 (2.3%)1.000
Skin reactionsa,n(%)11 (7.6%)9 (8.9%)2 (4.6%)0.506
Anemia,n(%)7 (4.8%)5 (4.9%)2 (4.6%)1.000
Requiring erythropoietin2 (1.3%)2 (1.9%)0 
Requiring RBV dose adjustment4 (2.7%)2 (1.9%)2 (4.6%) 
Requiring hospitalization1 (0.7%)1 (0.9%)0 
Gastrointestinal toxicityb,n(%)11 (7.6%)9 (8.9%)2 (4.6%)0.506
Cardiac disordersc,n(%)6 (4.1%)5 (4.9%)1 (2.3%)0.669
Neurological symtomps,n(%)26 (18.0%)20 (19.8%)6 (13.9%)0.483
Asthenia15 (10.4%)12 (11.8%)3 (6.9%)0.553
Headache10 (6.9%)9 (8.9%)1 (2.3%)0.281
Insomnia8 (5.5%)6 (5.9%)2 (4.6%)1.000
Amnesia1 (0.7%)1 (0.9%)01.000
Seizures1 (0.7%)01 (2.4%)0.298
Psychiatric symtomps,n(%)8 (5.5%)8 (7.9%)00.105
Anxiety1 (0.7%)1 (0.9%)01.000
Mood disorders7 (4.8%)7 (6.9%)00.103
  1. Legend:a-rash, pruritus, photosensitivity;
  2. b- diarrhea/constipation, dyspepsia, nausea;
  3. c-hyper/hypotension, arrhythmias